Πέμπτη 31 Μαΐου 2018

Combo Therapy for Lung Cancer Extends Survival [News in Brief]

The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non–small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in patients who received chemotherapy alone.



https://ift.tt/2J9OeyF

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου